FibroGen Inc (FGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FibroGen Inc (FGEN) has a cash flow conversion efficiency ratio of -0.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.85 Million) by net assets ($17.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of FibroGen Inc to measure how much of total assets are equity-financed.
FibroGen Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how FibroGen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check FGEN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
FibroGen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroGen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
-0.276x |
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
0.014x |
|
Retail Food Group Ltd
AU:RFG
|
0.000x |
|
Kalina Power Ltd
AU:KPO
|
1.221x |
|
REDCO PRP GROUP LTD -05
F:8KI
|
N/A |
|
Kirklands Inc
NASDAQ:KIRK
|
0.190x |
|
KL-Net Corp
KQ:039420
|
0.044x |
|
Rising Dragon Acquisition Corp. Ordinary Shares
NASDAQ:RDAC
|
-0.002x |
Annual Cash Flow Conversion Efficiency for FibroGen Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of FibroGen Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see FibroGen Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more